Industry Strength Score
31/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CYBIN INC (CYBN) Stock Price & Overview
NYSEARCA:CYBN • CA23256X4075
Current stock price
8.28 USD
+0.1 (+1.22%)
At close:
8.4468 USD
+0.17 (+2.01%)
After Hours:
The current stock price of CYBN is 8.28 USD. Today CYBN is up by 1.22%. In the past month the price increased by 47.07%. In the past year, price decreased by -18.02%.
CYBN Key Statistics
52-Week Range4.81 - 10.73
Current CYBN stock price positioned within its 52-week range.
1-Month Range5.61 - 9.12
Current CYBN stock price positioned within its 1-month range.
- Market Cap
- 413.089M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
CYBN Stock Performance
Today
+1.22%
1 Week
+1.47%
1 Month
+47.07%
3 Months
+36.18%
Longer-term
6 Months +4.28%
1 Year -18.02%
2 Years -42.66%
3 Years -43.84%
5 Years N/A
10 Years N/A
CYBN Stock Chart
CYBN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CYBN. When comparing the yearly performance of all stocks, CYBN turns out to be only a medium performer in the overall market: it outperformed 58.99% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CYBN Earnings
Next Earnings DateFeb 9, 2026
Last Earnings DateNov 13, 2025
PeriodQ2 / 2026
EPS Reported-CA$1.63
Revenue Reported
EPS Surprise -67.47%
Revenue Surprise %
CYBN Forecast & Estimates
Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
CYBN Financial Highlights
Income Statements
Revenue(TTM)N/A
Net Income(TTM)N/A
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
CYBN Ownership
Ownership
Inst Owners27.15%
Shares49.89M
Float41.00M
Ins Owners14.91%
Short Float %N/A
Short RatioN/A
CYBN Industry Overview
CYBN operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 29 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
48/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
39%
Outperformed 39% of sub-industries
3 Month Rank
62%
Outperformed 62% of sub-industries
6 Month Rank
25%
Outperformed 25% of sub-industries
Industry Fundamentals & Breadth
- Members
- 29
- New Highs
- 3.5%
- New Lows
- 10.3%
- Average ROE
- 17.4%
- Average Profit Margin
- 10%
- Average Operating Margin
- 19.1%
- Average P/E
- 5.3
- Average Fwd P/E
- 17.6
- Average Debt/Equity
- 0.5
CYBN Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.73 | 804.24B | ||
| JNJ | JOHNSON & JOHNSON | 18.12 | 547.597B | ||
| MRK | MERCK & CO. INC. | 21.44 | 274.033B | ||
| PFE | PFIZER INC | 8.93 | 149.376B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.57 | 117.584B | ||
| ZTS | ZOETIS INC | 16.26 | 47.868B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 28.553B | ||
| VTRS | VIATRIS INC | 5.99 | 17.431B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.26 | 10.887B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.409B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.108B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.796B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.73 | 4.956B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYBN
Company Profile
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Company Info
IPO: 2018-01-05
CYBIN INC
100 King Street West, Suite 5600
TORONTO ONTARIO CA
CEO: Doug Drysdale
Employees: 50
Phone: 19087648385
CYBIN INC / CYBN FAQ
Can you describe the business of CYBIN INC?
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Can you provide the latest stock price for CYBIN INC?
The current stock price of CYBN is 8.28 USD. The price increased by 1.22% in the last trading session.
Does CYBN stock pay dividends?
CYBN does not pay a dividend.
What is the ChartMill rating of CYBIN INC stock?
CYBN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the market cap for CYBIN INC?
CYBIN INC (CYBN) has a market capitalization of 413.09M USD. This makes CYBN a Small Cap stock.
What is the next earnings date for CYBN stock?
CYBIN INC (CYBN) will report earnings on 2026-02-09.